Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.

por Molthoff, C. F., Pinedo, H. M., Schlüper, H. M., Nijman, H. W., Boven, E.
Publicado 1992

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

por Gooden, M J M, de Bock, G H, Leffers, N, Daemen, T, Nijman, H W
Publicado 2011

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

por Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J., Daemen, T., Nijman, H. W.
Publicado 2011

Flexible assertive community treatment for individuals with a mild intellectual disability or borderline intellectual functioning: results of a longitudinal study in the Netherland...

por Neijmeijer, L. J., Korzilius, H. P. L. M., Kroon, H., Nijman, H. L. I., Didden, R.
Publicado 2019

Associations of sympathetic and parasympathetic activity in job stress and burnout: A systematic review

por de Looff, P. C., Cornet, L. J. M., Embregts, P. J. C. M., Nijman, H. L. I., Didden, H. C. M.
Publicado 2018

Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[(11)C]Methyl-AMD3465 PET

por Hartimath, SV, Draghiciu, O., Daemen, T, Nijman, H.W., van Waarde, A., Dierckx, R.A.J.O., de Vries, E.F.J.
Publicado 2019

Safewards: the empirical basis of the model and a critical appraisal

por Bowers, L, Alexander, J, Bilgin, H, Botha, M, Dack, C, James, K, Jarrett, M, Jeffery, D, Nijman, H, Owiti, J A, Papadopoulos, C, Ross, J, Wright, S, Stewart, D
Publicado 2014

Diagnose, indicate, and treat severe mental illness (DITSMI) as appropriate care: A three-year follow-up study in long-term residential psychiatric patients on the effects of re-di...

por Veereschild, H. M., Noorthoorn, E. O., Nijman, H. L. I., Mulder, C. L., Dankers, M., Van der Veen, J. A., Loonen, A. J. M., Hutschemaekers, G. J. M.
Publicado 2020

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity

por Gooden, M J M, Wiersma, V R, Boerma, A, Leffers, N, Boezen, H M, ten Hoor, K A, Hollema, H, Walenkamp, A M E, Daemen, T, Nijman, H W, Bremer, E
Publicado 2014

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer

por Leffers, N, Fehrmann, R S N, Gooden, M J M, Schulze, U R J, ten Hoor, K A, Hollema, H, Boezen, H M, Daemen, T, de Jong, S, Nijman, H W, van der Zee, A G J
Publicado 2010

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters

por Versluis, M A, de Jong, R A, Plat, A, Bosse, T, Smit, V T, Mackay, H, Powell, M, Leary, A, Mileshkin, L, Kitchener, H C, Crosbie, E J, Edmondson, R J, Creutzberg, C L, Hollema, H, Daemen, T, de Bock, G H, Nijman, H W
Publicado 2015

TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial

por Koeneman, M. M., Kruse, A. J., Kooreman, L. F. S., zur Hausen, A., Hopman, A. H. N., Sep, S. J. S., Van Gorp, T., Slangen, B. F. M., van Beekhuizen, H. J., van de Sande, M., Gerestein, C. G., Nijman, H. W., Kruitwagen, R. F. P. M.
Publicado 2016

Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial

por Koeneman, M. M., Kruse, A. J., Kooreman, L. F. S., zur Hausen, A., Hopman, A. H. N., Sep, S. J. S., Van Gorp, T., Slangen, B. F. M., van Beekhuizen, H. J., van de Sande, A. J. M., Gerestein, C. G., Nijman, H. W., Kruitwagen, R. F. P. M.
Publicado 2017

Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients

por Paijens, S. T., Vledder, A., Loiero, D., Duiker, E. W., Bart, J., Hendriks, A. M., Jalving, M., Workel, H. H., Hollema, H., Werner, N., Plat, A., Wisman, G. B. A., Yigit, R., Arts, H., Kruse, A. J., de Lange, N.M., Koelzer, V. H., de Bruyn, M., Nijman, H. W.
Publicado 2021

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

por Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.
Publicado 2018